Pacira Reports Record Fourth Quarter and Full-Year Revenues
— Full-year 2019 revenue increases 25 percent to
— Total 2020 revenue guidance of between
— Anesthesia-driven regional approaches are expanding and driving strong EXPAREL growth —
— Conference call today at
“By every measure, 2019 was an outstanding year for Pacira. We are delighted to report record revenues for EXPAREL® with our sixth consecutive quarter of more than 20 percent growth,” said
“Looking forward, we intend to capitalize on this momentum with robust topline growth that will drive substantial operating leverage and cash flow, providing significant financial flexibility to invest in future growth opportunities. Our mission for 2020 remains steadfast as we continue to propel our global leadership in non-opioid pain management and deliver multiple milestones, including the publication of new data in C-section, label-expansion initiatives for pediatrics and lower extremity nerve block, and the advancement of regulatory activities in
2019 Full-Year and Fourth Quarter Financial Highlights
- Full-year revenues of
$421.0 million and fourth quarter revenues of$122.4 million . - Full-year EXPAREL® (bupivacaine liposome injectable suspension) net product sales of
$407.9 million and fourth quarter EXPAREL net product sales of$116.9 million . - Full-year iovera° net product sales were
$7.9 million and fourth quarter iovera° net product sales of$3.2 million . Pacira began recognizing sales of iovera° inApril 2019 after completing its acquisition ofMyoScience, Inc. , a privately held medical technology company. - Full-year GAAP net loss of
$11.0 million or$0.27 per share (basic and diluted). - Full-year non-GAAP net income of
$70.7 million or$1.67 per diluted share. - Fourth quarter GAAP net loss of
$4.9 million or$0.12 per share (basic and diluted). - Fourth quarter non-GAAP net income of
$23.8 million or$0.56 per diluted share.
Recent Highlights
- Launch of national regional anesthesia training initiative with Envision Physician Services.
InJanuary 2020 , Pacira announced a collaboration with Envision Physician Services to train anesthesiology clinicians on ultrasound-guided regional anesthesia techniques utilizing long-acting local anesthetics like EXPAREL via a series of interactive workshops held across the country. The program supports the ongoing efforts by both organizations to advance the delivery of high-quality, patient-centered care.
- EXPAREL achieves primary and key secondary endpoints in Phase 4 CHOICE study in cesarean section patients. In
January 2020 , Pacira announced that its Phase 4 study of EXPAREL in patients undergoing Cesarean section achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption while maintaining pain scores through 72 hours (P≤0.001). EXPAREL demonstrated statistical significance for the key secondary endpoint of a reduction in the incidence and severity of itching for 72 hours after surgery (P≤0.05). Full study results will be submitted for publication in the peer-reviewed medical literature later this year.
- Phase 3 PLAY study of EXPAREL in pediatric patients achieves positive results. In
December 2019 , Pacira announced positive results from its Phase 3 PLAY study of EXPAREL administered as a single-dose infiltration in pediatric patients undergoing spinal or cardiac surgeries. Overall findings were consistent with the pharmacokinetic and safety profiles for adult patients with no safety concerns identified at a dose of 4 mg/kg. These results will provide the foundation for the company’s supplemental New Drug Application submission in the first half of 2020 to theU.S. Food and Drug Administration (FDA ) seeking expansion of the EXPAREL label to include children aged six and over.
Fourth Quarter 2019 Financial Results
- Total revenues were
$122.4 million in the fourth quarter of 2019, a 29% increase over the$95.1 million reported for the fourth quarter of 2018.
- EXPAREL net product sales were
$116.9 million in the fourth quarter of 2019, a 24% increase over the$94.4 million reported for the fourth quarter of 2018.
- Fourth quarter iovera° net product sales were
$3.2 million . Pacira began recognizing sales of iovera° inApril 2019 after completing its acquisition ofMyoScience, Inc. , a privately held medical technology company.
- Sales of bupivacaine liposome injectable suspension to a third-party licensee for use in veterinary practice were
$1.7 million in the fourth quarter of 2019, compared to$0.3 million in 2018.
- Fourth quarter royalty revenue was
$0.6 million compared to$0.4 million in 2018.
- Total operating expenses were
$120.7 million in the fourth quarter of 2019, compared to$82.9 million in the fourth quarter of 2018.
- Research and development (R&D) expenses were
$19.7 million in the fourth quarter of 2019, compared to$14.2 million in the fourth quarter of 2018. The company’s R&D expenses include$8.7 million and$6.5 million of product development and manufacturing capacity expansion costs in the fourth quarters of 2019 and 2018, respectively.
- Selling, general and administrative (SG&A) expenses were
$54.2 million in the fourth quarter of 2019, compared to$44.6 million in the fourth quarter of 2018.
- GAAP net loss was
$4.9 million , or$0.12 per share (basic and diluted) in the fourth quarter of 2019, compared to GAAP net income of$8.3 million , or$0.20 per share (basic and diluted), in the fourth quarter of 2018.
- Non-GAAP net income was
$23.8 million , or$0.57 per share (basic) and$0.56 per share (diluted), in the fourth quarter of 2019, compared to non-GAAP net income of$19.8 million , or$0.48 per share (basic) and$0.47 per share (diluted), in the fourth quarter of 2018.
- Pacira had 41.8 million basic weighted average shares of common stock outstanding in the fourth quarter of 2019.
- For non-GAAP measures, Pacira had 42.6 million diluted weighted average shares of common stock outstanding in the fourth quarter of 2019.
Full-Year 2019 Financial Results
- Total revenues were
$421.0 million in 2019, a 25% increase over the$337.3 million reported in 2018.
- EXPAREL net product sales were
$407.9 million in 2019, a 23% increase over the$331.1 million reported in 2018.
- Full-year iovera° net product sales were
$7.9 million . Pacira began recognizing sales of iovera° inApril 2019 after completing its acquisition ofMyoScience, Inc. , a privately held medical technology company.
- Sales of bupivacaine liposome injectable suspension to a third-party licensee for use in veterinary practice were
$3.2 million in 2019, compared to$1.3 million in 2018.
- Full-year royalty revenue was
$2.1 million compared to$1.9 million in 2018.
- Total operating expenses were
$410.5 million in 2019, compared to$321.4 million in 2018.
- Research and development (R&D) expenses were
$72.1 million in 2019, compared to$55.7 million in 2018. The company’s R&D expenses include$29.7 million and$28.5 million of product development and manufacturing capacity expansion costs in 2019 and 2018, respectively.
- Selling, general and administrative (SG&A) expenses were
$200.8 million in 2019, compared to$177.3 million in 2018.
- GAAP net loss was
$11.0 million , or$0.27 per share (basic and diluted) in 2019, compared to a GAAP net loss of$0.5 million , or$0.01 per share (basic and diluted) in 2018.
- Non-GAAP net income was
$70.7 million , or$1.70 per share (basic) and$1.67 per share (diluted), in 2019, compared to non-GAAP net income of$43.5 million , or$1.06 per share (basic) and$1.04 per share (diluted), in 2018.
- Pacira ended 2019 with cash, cash equivalents, short-term and long-term investments (“cash”) of
$356.7 million . Cash provided by operations was $70.5 million in 2019, compared to $48.9 million in 2018.
- Pacira had 41.5 million basic weighted average shares of common stock outstanding in 2019.
- For non-GAAP measures, Pacira had 42.4 million diluted weighted average shares of common stock outstanding in 2019.
2020 Outlook
Pacira announces its full-year 2020 financial guidance as follows. Pacira expects:
- Total revenues to be between
$485 million and $500 million ;
- EXPAREL net product sales to be between
$465 million and $475 million ;
- iovera° net product sales to be between
$15 million and $20 million ;
- Non-GAAP gross margins to be between 76% and 78%;
- Non-GAAP research and development (R&D) expense to be between
$60 million to $70 million ;
- Non-GAAP selling, general and administrative (SG&A) expense to be between
$180 million and $190 million ; and
- Stock-based compensation to be between
$35 million and $40 million .
See “Non-GAAP Financial Information” and “Reconciliations of GAAP to Non-GAAP 2020 Financial Guidance” below.
Today’s Conference Call and Webcast Reminder
The Pacira management team will host a conference call to discuss the company’s financial results and recent developments today, Thursday, February 20, 2020, at
For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-404-537-3406 (international) using the passcode 8765839. The replay of the call will be available for one week from the date of the live call. The webcast will be available on the Pacira website for approximately two weeks following the call.
Non-GAAP Financial Information
This press release contains financial measures that do not comply with U.S. generally accepted accounting principles (GAAP), such as non-GAAP net income, non-GAAP net income per share, non-GAAP cost of goods sold, non-GAAP gross margins, non-GAAP research and development (R&D) expense and non-GAAP selling, general and administrative (SG&A) expense, because such measures exclude milestone revenue; acquisition-related charges, product discontinuation costs and other expense; stock-based compensation; amortization of debt discount; amortization of acquired intangible assets; an income tax benefit and step-up in basis of inventory in connection with the acquisition of
These measures supplement Pacira’s financial results prepared in accordance with GAAP. Pacira management uses these measures to better analyze its financial results, estimate its future cost of goods sold, gross margins, R&D expense and SG&A expense outlook for 2020 and to help make managerial decisions. In management’s opinion, these non-GAAP measures are useful to investors and other users of our financial statements by providing greater transparency into the operating performance at Pacira and its future outlook. Such measures should not be deemed to be an alternative to GAAP requirements or a measure of liquidity for Pacira. Non-GAAP measures are also unlikely to be comparable with non-GAAP disclosures released by other companies. See the tables below for a reconciliation of GAAP to non-GAAP measures, and a reconciliation of our GAAP to non-GAAP 2020 financial guidance for gross margins, R&D expense and SG&A expense.
About
About EXPAREL
EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.
Important Safety Information for Patients
EXPAREL should not be used in obstetrical paracervical block anesthesia. In studies where EXPAREL was injected into the wound, the most common side effects were nausea, constipation, and vomiting. In studies where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation. EXPAREL is not recommended to be used in patients younger than 18 years old or in pregnant women. Tell your healthcare provider if you have liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from your body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL: can affect your nervous system and your cardiovascular system; may cause an allergic reaction; may cause damage if injected into your joints.
About iovera°
The iovera° system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. In one study, the majority of the patients suffering from osteoarthritis of the knee experienced pain and system relief beyond 150 days.1 The iovera° system’s “1×90” Smart Tip configuration (indicating one needle which is 90 mm long) can also facilitate target nerve location by conducting electrical nerve stimulation from a separate nerve stimulator. The iovera° system is not indicated for treatment of central nervous system tissue.
1Radnovich, R. et al. “Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial.” Osteoarthritis and Cartilage (2017) p1-10.
Important Safety Information
The iovera° system is contraindicated for use in patients with the following: Cryoglobulinemia; Paroxysmal cold hemoglobinuria; cold urticaria; Raynaud’s disease; open and/or infected wounds at or near the treatment line. Potential complications: As with any surgical treatment that uses needle-based therapy, there is potential for temporary site-specific reactions, including but not limited to: bruising (ecchymosis); swelling (edema); inflammation and/or redness (erythema); pain and/or tenderness; altered sensation (localized dysesthesia). Typically, these reactions resolve with no physician intervention. Patients may help the healing process by applying ice packs to the affected sites, and by taking over-the-counter analgesics.
Forward-Looking Statements
Any statements in this press release about the company’s future expectations, plans, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the success of the company’s sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and the company’s ability to serve those markets; the company’s plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; the ability to realize anticipated benefits and synergies from the acquisition of MyoScience; the ability to successfully integrate iovera° and any other future acquisitions into the company’s existing business; the commercial success of iovera° and other factors discussed in the “Risk Factors” of the company’s most recent Annual Report on Form 10-K and in other filings that the company periodically makes with the
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
| December 31, 2019 |
December 31, 2018 |
||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash, cash equivalents and short-term investments | $ | 291,950 | $ | 383,454 | |||||||
| Accounts receivable, net | 47,530 | 38,000 | |||||||||
| Inventories, net | 58,296 | 48,569 | |||||||||
| Prepaid expenses and other current assets | 10,781 | 7,946 | |||||||||
| Total current assets | 408,557 | 477,969 | |||||||||
| Long-term investments | 64,798 | 25,871 | |||||||||
| Fixed assets, net | 104,681 | 108,670 | |||||||||
| Right-of-use assets, net | 38,124 | — | |||||||||
| Goodwill | 99,547 | 62,040 | |||||||||
| Intangible assets, net | 104,387 | — | |||||||||
| Equity investment and other assets | 10,971 | 14,803 | |||||||||
| Total assets | $ | 831,065 | $ | 689,353 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 12,799 | $ | 14,368 | |||||||
| Accrued expenses | 70,427 | 45,865 | |||||||||
| Lease liabilities | 4,935 | — | |||||||||
| Convertible senior notes (1) | — | 338 | |||||||||
| Contingent consideration | 18,179 | — | |||||||||
| Income taxes payable | 1,333 | 90 | |||||||||
| Total current liabilities | 107,673 | 60,661 | |||||||||
| Convertible senior notes (2) | 306,045 | 290,592 | |||||||||
| Lease liabilities | 40,938 | — | |||||||||
| Contingent consideration | 19,963 | — | |||||||||
| Other liabilities | 1,502 | 16,874 | |||||||||
| Total stockholders’ equity | 354,944 | 321,226 | |||||||||
| Total liabilities and stockholders’ equity | $ | 831,065 | $ | 689,353 | |||||||
(1) Relates to our 3.25% convertible senior notes due 2019 that matured on
(2) Relates to our 2.375% convertible senior notes due 2022 that are not currently convertible.
Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)
| Three Months Ended | Year Ended | ||||||||||||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||||||||||||
| 2019 | 2018 | 2019 | 2018 | ||||||||||||||||||||||||||||
| Net product sales: | 2019 | 2018 | |||||||||||||||||||||||||||||
| EXPAREL | $ | 116,939 | $ | 94,422 | $ | 407,877 | $ | 331,112 | |||||||||||||||||||||||
| Bupivacaine liposome injectable suspension | 1,685 | 293 | 3,153 | 1,315 | |||||||||||||||||||||||||||
| Total EXPAREL / bupivacaine liposome injectable suspension net product sales | 118,624 | 94,715 | 411,030 | 332,427 | |||||||||||||||||||||||||||
| iovera° | 3,221 | — | 7,896 | — | |||||||||||||||||||||||||||
| Total net product sales | 121,845 | 94,715 | 418,926 | 332,427 | |||||||||||||||||||||||||||
| Collaborative licensing and milestone revenue | — | — | — | 3,000 | |||||||||||||||||||||||||||
| Royalty revenue | 579 | 400 | 2,100 | 1,850 | |||||||||||||||||||||||||||
| Total revenues | 122,424 | 95,115 | 421,026 | 337,277 | |||||||||||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||||||||||
| Cost of goods sold | 31,904 | 23,979 | 106,712 | 86,845 | |||||||||||||||||||||||||||
| Research and development | 19,653 | 14,174 | 72,119 | 55,688 | |||||||||||||||||||||||||||
| Selling, general and administrative | 54,223 | 44,647 | 200,782 | 177,265 | |||||||||||||||||||||||||||
| Amortization of acquired intangible assets | 1,967 | — | 5,703 | — | |||||||||||||||||||||||||||
| Acquisition-related charges, product discontinuation and other | 12,965 | 53 | 25,230 | 1,564 | |||||||||||||||||||||||||||
| Total operating expenses | 120,712 | 82,853 | 410,546 | 321,362 | |||||||||||||||||||||||||||
| Income from operations | 1,712 | 12,262 | 10,480 | 15,915 | |||||||||||||||||||||||||||
| Other income (expense): | |||||||||||||||||||||||||||||||
| Interest income | 1,667 | 2,004 | 7,376 | 6,497 | |||||||||||||||||||||||||||
| Interest expense | (5,997 | ) | (5,753 | ) | (23,628 | ) | (21,949 | ) | |||||||||||||||||||||||
| Other, net | (923 | ) | (191 | ) | (4,976 | ) | (888 | ) | |||||||||||||||||||||||
| Total other expense, net | (5,253 | ) | (3,940 | ) | (21,228 | ) | (16,340 | ) | |||||||||||||||||||||||
| Income (loss) before income taxes | (3,541 | ) | 8,322 | (10,748 | ) | (425 | ) | ||||||||||||||||||||||||
| Income tax expense | (1,347 | ) | (37 | ) | (268 | ) | (46 | ) | |||||||||||||||||||||||
| Net income (loss) | $ | (4,888 | ) | $ | 8,285 | $ | (11,016 | ) | $ | (471 | ) | ||||||||||||||||||||
| Net income (loss) per share: | |||||||||||||||||||||||||||||||
| Basic and diluted net income (loss) per common share | $ | (0.12 | ) | $ | 0.20 | $ | (0.27 | ) | $ | (0.01 | ) | ||||||||||||||||||||
| Weighted average common shares outstanding: | |||||||||||||||||||||||||||||||
| Basic | 41,784 | 41,148 | 41,513 | 40,911 | |||||||||||||||||||||||||||
| Diluted | 41,784 | 42,219 | 41,513 | 40,911 | |||||||||||||||||||||||||||
Reconciliation of GAAP to Non-GAAP Financial Information
(in thousands, except per share amounts)
(unaudited)
| Three Months Ended | Year Ended | ||||||||||||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||||||||||||
| 2019 | 2018 | 2019 | 2018 | ||||||||||||||||||||||||||||
| GAAP net income (loss) | $ | (4,888 | ) | $ | 8,285 | $ | (11,016 | ) | $ | (471 | ) | ||||||||||||||||||||
| Non-GAAP adjustments: | |||||||||||||||||||||||||||||||
| Milestone revenue (1) | — | — | — | (3,000 | ) | ||||||||||||||||||||||||||
| Acquisition-related charges, product discontinuation and other | 12,965 | 53 | 25,230 | 1,564 | |||||||||||||||||||||||||||
| Stock-based compensation | 9,189 | 8,186 | 33,650 | 31,725 | |||||||||||||||||||||||||||
| Amortization of debt discount | 3,530 | 3,286 | 13,746 | 12,799 | |||||||||||||||||||||||||||
| Amortization of acquired intangible assets | 1,967 | — | 5,703 | — | |||||||||||||||||||||||||||
| Income tax benefit in connection with acquisition | — | — | (1,828 | ) | — | ||||||||||||||||||||||||||
| Recognition of step-up basis in inventory from acquisition | — | — | 220 | — | |||||||||||||||||||||||||||
| Loss on investment and other non-operating income, net | 1,023 | — | 4,981 | 854 | |||||||||||||||||||||||||||
| Total Non-GAAP adjustments | 28,674 | 11,525 | 81,702 | 43,942 | |||||||||||||||||||||||||||
| Non-GAAP net income | $ | 23,786 | $ | 19,810 | $ | 70,686 | $ | 43,471 | |||||||||||||||||||||||
| GAAP basic and diluted net income (loss) per common share | $ | (0.12 | ) | $ | 0.20 | $ | (0.27 | ) | $ | (0.01 | ) | ||||||||||||||||||||
| Non-GAAP basic net income per common share | $ | 0.57 | $ | 0.48 | $ | 1.70 | $ | 1.06 | |||||||||||||||||||||||
| Non-GAAP diluted net income per common share | $ | 0.56 | $ | 0.47 | $ | 1.67 | $ | 1.04 | |||||||||||||||||||||||
| Weighted average common shares outstanding - basic | 41,784 | 41,148 | 41,513 | 40,911 | |||||||||||||||||||||||||||
| Weighted average common shares outstanding - diluted | 42,612 | 42,219 | 42,370 | 41,869 | |||||||||||||||||||||||||||
| Cost of goods sold reconciliation: | |||||||||||||||||||||||||||||||
| GAAP cost of goods sold | $ | 31,904 | $ | 23,979 | $ | 106,712 | $ | 86,845 | |||||||||||||||||||||||
| Stock-based compensation | (1,174 | ) | (1,047 | ) | (4,665 | ) | (4,478 | ) | |||||||||||||||||||||||
| Recognition of step-up basis in inventory from acquisition | — | — | (220 | ) | — | ||||||||||||||||||||||||||
| Non-GAAP cost of goods sold | $ | 30,730 | $ | 22,932 | $ | 101,827 | $ | 82,367 | |||||||||||||||||||||||
| Research and development reconciliation: | |||||||||||||||||||||||||||||||
| GAAP research and development | $ | 19,653 | $ | 14,174 | $ | 72,119 | $ | 55,688 | |||||||||||||||||||||||
| Stock-based compensation | (1,342 | ) | (1,164 | ) | (5,114 | ) | (3,934 | ) | |||||||||||||||||||||||
| Non-GAAP research and development | $ | 18,311 | $ | 13,010 | $ | 67,005 | $ | 51,754 | |||||||||||||||||||||||
| Selling, general and administrative reconciliation: | |||||||||||||||||||||||||||||||
| GAAP selling, general and administrative | $ | 54,223 | $ | 44,647 | $ | 200,782 | $ | 177,265 | |||||||||||||||||||||||
| Stock-based compensation | (6,672 | ) | (5,975 | ) | (23,871 | ) | (23,313 | ) | |||||||||||||||||||||||
| Non-GAAP selling, general and administrative | $ | 47,551 | $ | 38,672 | $ | 176,911 | $ | 153,952 | |||||||||||||||||||||||
(1) Represents a
Reconciliation of GAAP to Non-GAAP 2020 Financial Guidance
(dollars in millions)
| GAAP to Non-GAAP Guidance | GAAP | Stock-Based Compensation | Non-GAAP | |||
| Total revenues | $485 to $500 | — | — | |||
| EXPAREL net product sales | $465 to $475 | — | — | |||
| iovera° net product sales | $15 to $20 | — | — | |||
| Gross margin | 75% to 77% | Approx. 1% | 76% to 78% | |||
| Research and development expense | $64 to $76 | $4 to $6 | $60 to $70 | |||
| Selling, general and administrative expense | $207 to $219 | $27 to $29 | $180 to $190 | |||
| Stock-based compensation | $35 to $40 | — | — |
Investor Contact:Susan Mesco , (973) 451-4030 susan.mesco@pacira.com Media Contact: Coyne Public RelationsAlyssa Schneider , (973) 588-2270 aschneider@coynepr.com
Source: Pacira BioSciences